Everest Organics develops new API to treat Covid-19

12 Oct 2021 Evaluate

Everest Organics has unveiled the successful development of an anti-viral API 'MOLNUPIRAVIR' an additional COVID -19 treatment drug that is being developed at Lab Scale for the first-line treatment of COVID-19 in adults patients with mild to moderate symptoms. Everest is planning and preparing to be an active player in viral segment in the upcoming future.

Everest Organics is a fast growing API and Bulk drug manufacturing company with world class facility and it is committed to manufacturing excellent quality products and customer service.

Everest Organics Share Price

311.25 -2.00 (-0.64%)
09-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.10
Dr. Reddys Lab 1095.15
Cipla 1416.30
Lupin 1921.30
Zydus Lifesciences 844.60
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...